Insider Transactions in Q1 2021 at Ani Pharmaceuticals Inc (ANIP)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2021
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
508
-0.44%
|
$18,288
$36.14 P/Share
|
|
Mar 31
2021
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
278
-0.24%
|
$10,008
$36.14 P/Share
|
|
Mar 29
2021
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
953
-0.81%
|
$30,496
$32.68 P/Share
|
|
Mar 29
2021
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
524
-0.45%
|
$16,768
$32.68 P/Share
|
|
Mar 29
2021
|
Robert W Schrepfer SVP - NEW BUS DEV & SPEC SALES |
SELL
Payment of exercise price or tax liability
|
Direct |
5,566
-5.98%
|
$178,112
$32.68 P/Share
|
|
Mar 23
2021
|
Patrick D Walsh Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,292
+16.11%
|
-
|
|
Mar 23
2021
|
Robert E. Brown Jr |
BUY
Grant, award, or other acquisition
|
Direct |
9,292
+19.25%
|
-
|
|
Mar 23
2021
|
Thomas Haughey Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,292
+25.12%
|
-
|
|
Mar 23
2021
|
David Nash Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,292
+30.03%
|
-
|
|
Mar 23
2021
|
Jeanne Thoma Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,292
+35.73%
|
-
|
|
Mar 23
2021
|
Antonio R Pera Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,292
+35.73%
|
-
|
|
Mar 23
2021
|
Nikhil Lalwani PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
136,495
+45.27%
|
-
|
|
Mar 23
2021
|
Stephen P. Carey SVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
54,470
+31.65%
|
-
|
|
Mar 23
2021
|
James G. Marken SVP OPS & PROD DEV |
BUY
Grant, award, or other acquisition
|
Direct |
32,041
+21.45%
|
-
|
|
Mar 15
2021
|
Patrick D Walsh Director |
BUY
Open market or private purchase
|
Direct |
4,000
+9.28%
|
$128,000
$32.89 P/Share
|
|
Feb 15
2021
|
Ori Gutwerg SVP, GENERICS |
BUY
Grant, award, or other acquisition
|
Direct |
12,907
+50.0%
|
-
|
|
Feb 15
2021
|
Christopher Mutz HEAD OF RARE DISEASE |
BUY
Grant, award, or other acquisition
|
Direct |
16,134
+50.0%
|
-
|